IDEAYA Biosciences presents a high-risk, high-reward opportunity driven by its synthetic lethality pipeline, but its financial profile is characterized by extreme volatility tied to one-time collaboration milestones.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | -$1.22-3.4% vs -$1.18 | $10M+35.1% vs $8M |
Q3 2026 Aug 4, 2026 | -$1.22-15.1% vs -$1.06 | $9M+10.4% vs $8M |
Q2 2026 May 5, 2026 | -$1.11-3.7% vs -$1.07 | $7M+30.2% vs $5M |
Q1 2026 Feb 17, 2026 | -$0.94+1.2% vs -$0.95 | $11M+72.5% vs $6M |
SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its participation in the upcoming investor relations events.
IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to earnings of $1.33 per share a year ago.
Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanoma in both primary and metastatic disease, irrespective of HLA-A*02:01 allele status or line of therapy Completed NDA submission in Q3'26 to support the potential U.S. approval of darovasertib plus crizotinib in metastatic uveal melanoma Updated data from Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 TOP1 ADC) presented at ESMO 2026 demonstrates robust anti-tumor activity and encouraging survival benefit in relapsed small cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC); initial data from IDEAYA-sponsored global Phase 1/2 trial expected by the end of 2026 / early 2027 IDEAYA R&D Day scheduled for November 16th to highlight preclinical data supporting rational combinations that exploit MTAP/CDKN2A deficiency in KRAS-mutant cancers $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026; cash runway guidance into 2030 remains unchanged based on current operating plan SOUTH SAN FRANCISCO, Calif., Nov. 3, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeutics, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeutics, today announced that, on October 29, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 99,600 shares of the Company's common stock to four newly hired employees.
Benchmark IDYA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for IDEAYA Biosciences, Inc. (IDYA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $31.24 | $2.74B | -7.66 | 3024.43% | -1149.62% | -39.52% | — | |
| $4.37 | $177.42M | 8.17 | 55.25% | 58.87% | 6.24% | 23.45% | |
| $7.15 | $297.74M | 21.19 | 10.37% | 20.98% | — | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — |
IDEAYA Biosciences, Inc. (IDYA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
IDEAYA Biosciences, Inc. (IDYA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
May 5, 2026·SEC
May 5, 2026·SEC
Get notified when IDYA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IDEAYA Biosciences, Inc. (IDYA) stock FAQ — growth, dividends, profitability & financials explained
IDEAYA Biosciences, Inc. (IDYA) reported $36.5M in revenue over the trailing twelve months. Revenue was $218.7M in fiscal year 2025.
IDEAYA Biosciences, Inc. (IDYA) revenue fell by 83.0% over the trailing twelve months, compared with the twelve months before.
No. IDEAYA Biosciences, Inc. (IDYA) reported a net loss of $420.0M over the trailing twelve months.
IDEAYA Biosciences, Inc. (IDYA) had a return on equity (ROE) of -39.5% over the trailing twelve months. A negative ROE means the company lost money over the period.
IDEAYA Biosciences, Inc. (IDYA) had negative free cash flow of $349.8M over the trailing twelve months.
